{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:00:44Z","timestamp":1772114444240,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00198-023-06931-3","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T21:01:11Z","timestamp":1696280471000},"page":"365-370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6501-3692","authenticated-orcid":false,"given":"Maria P.","family":"Yavropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4042","authenticated-orcid":false,"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2243-6940","authenticated-orcid":false,"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danai","family":"Georgakopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Papatheodorou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"6931_CR1","first-page":"dgaa756","volume":"26","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 26:dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"6931_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","volume":"21","author":"AS Solling","year":"2023","unstructured":"Solling AS, Tsourdi E, Harslof T, Langdahl BL (2023) Denosumab discontinuation. Curr Osteoporos Rep 21:95\u2013103","journal-title":"Curr Osteoporos Rep"},{"key":"6931_CR3","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106:e4155\u2013e4162","journal-title":"J Clin Endocrinol Metab"},{"key":"6931_CR4","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS Solling","year":"2021","unstructured":"Solling AS, Harslof T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 36:1245\u20131254","journal-title":"J Bone Miner Res"},{"key":"6931_CR5","doi-asserted-by":"publisher","first-page":"e1760","DOI":"10.1210\/clinem\/dgab627","volume":"107","author":"S Ferrari","year":"2022","unstructured":"Ferrari S (2022) Short or long-term osteoporosis therapy with denosumab? J Clin Endocrinol Metab 107:e1760\u2013e1762","journal-title":"J Clin Endocrinol Metab"},{"key":"6931_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19:307\u2013317","journal-title":"Nat Rev Rheumatol"},{"key":"6931_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11914-022-00756-5","volume":"20","author":"AS Kim","year":"2022","unstructured":"Kim AS, Girgis CM, McDonald MM (2022) Osteoclast recycling and the rebound phenomenon following denosumab discontinuation. Curr Osteoporos Rep 20:505\u2013515","journal-title":"Curr Osteoporos Rep"},{"key":"6931_CR8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","volume":"184","author":"MM McDonald","year":"2021","unstructured":"McDonald MM, Khoo WH, Ng PY et al (2021) Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184:1330-1347 e1313","journal-title":"Cell"},{"issue":"3","key":"6931_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/endrev\/bnac031","volume":"44","author":"M Schini","year":"2022","unstructured":"Schini M, Vilaca T, Gossiel F, Salam S, Eastell R (2022) Bone turnover markers: basic biology to clinical applications. Endocr Rev 44(3):417\u2013473","journal-title":"Endocr Rev"},{"key":"6931_CR10","first-page":"368","volume":"7","author":"A Kim","year":"2023","unstructured":"Kim A, Castro-Martinez A, Taylor V, Center J, Girgis C, Croucher P, McDonald MM (2023) Longitudinal changes in bone turnover and osteoclast activity following withdrawal of RANKL inhibition. JBMR Plus 7:368","journal-title":"JBMR Plus"},{"key":"6931_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"6931_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","volume":"176","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Yavropoulou MP, Makras P, Sakellariou GT, Papadopoulou F, Gerou S, Papapoulos SE (2017) Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 176:677\u2013683","journal-title":"Eur J Endocrinol"},{"key":"6931_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fendo.2020.00250","volume":"11","author":"K Jahn-Rickert","year":"2020","unstructured":"Jahn-Rickert K, Wolfel EM, Jobke B, Riedel C, Hellmich M, Werner M, McDonald MM, Busse B (2020) Elevated bone hardness under denosumab treatment, with persisting lower osteocyte viability during discontinuation. Front Endocrinol (Lausanne) 11:250","journal-title":"Front Endocrinol (Lausanne)"},{"key":"6931_CR14","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2-year clinical trial. J Bone Miner Res 34:2220\u20132228","journal-title":"J Bone Miner Res"},{"key":"6931_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bone.2019.03.019","volume":"123","author":"A Fassio","year":"2019","unstructured":"Fassio A, Adami G, Benini C et al (2019) Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone 123:191\u2013195","journal-title":"Bone"},{"key":"6931_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00198-022-06651-0","volume":"34","author":"AS Solling","year":"2023","unstructured":"Solling AS, Harslof T, Jorgensen NR, Langdahl B (2023) Changes in RANKL and TRAcP5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption. Osteoporos Int 34:599\u2013605","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06931-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06931-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06931-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T09:02:35Z","timestamp":1706864555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06931-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6931"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06931-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Polyzois Makras reports fees for lectures\/advisory boards and research grants from Amgen and Galenica and fees for lectures\/advisory boards from UCB, Elpen, Bianex, Eli-Lilly, ITF, Unipharma, and Rapharm; Maria P. Yavropoulou reports fees for lectures\/advisory boards and research grants from Galenica; Socrates E. Papapoulos reports consulting\/speaking fees from Amgen, Entera Bio, Qualix Dot, Radius Health and UCB; Athanasios D. Anastasilakis reports lecture fees from Amgen, Bianex, Eli-Lilly, Galenica, ITF, Unifarma, and UCB; Stergios A. Polyzos, Danai Georgakopoulou and Athanasios Papatheodorou have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest in respect to the article"}}]}}